Calcium channel blockers in the management of stable angina pectoris
- Joseph P Kannam, MD
Joseph P Kannam, MD
- Assistant Professor of Medicine
- Harvard Medical School
- Julian M Aroesty, MD
Julian M Aroesty, MD
- Clinical Associate Professor of Medicine
- Harvard Medical School
- Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
- Editor-in-Chief — Cardiovascular Medicine
- Section Editor — Coronary Heart Disease
- Section Editor — Myopericardial Disease
- Professor of Medicine
- Mayo Medical School
- Section Editor
- Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC, FAHA
Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC, FAHA
- Section Editor — Coronary Heart Disease
- Professor of Cardiovascular Science
- Head, Cardiovascular Sciences Research Centre
- St. George's, University of London
Calcium channel blockers are a heterogeneous group of compounds used in a variety of cardiovascular disorders such as stable angina pectoris, vasospastic angina, hypertension, hypertrophic cardiomyopathy, and supraventricular arrhythmias.
This topic review will present the major issues regarding the use of calcium channel blockers in the patient with stable angina and the evidence that these drugs are effective. Their role, compared with other drugs, in the overall management of angina is discussed separately. (See "Stable ischemic heart disease: Overview of care".)
MECHANISM OF ACTION
Calcium influx into the myocyte initiates a series of events essential for contractility. Calcium entry into the myocyte first triggers intracellular calcium release; the released calcium then binds the regulatory protein troponin, resulting in a calcium-troponin complex which allows actin and myosin to interact and contract. The sequence of events is the same in vascular smooth muscle cells, except that a calcium-calmodulin complex instead of calcium-troponin permits the interaction between actin and myosin. The net effect is vasodilatation; the ensuing fall in blood pressure decreases cardiac work and may contribute to the efficacy of these drugs in the patient with angina.
Calcium channel blockers work by blocking the initial calcium influx into myocytes and vascular smooth muscle cells, preventing the cascade of events detailed above. The available calcium channel blocking agents block receptors on the L-type calcium channel which gives rise to a slowly inactivating high threshold current in cardiac cells.
CARDIOVASCULAR AND ADVERSE SIDE EFFECTS
The currently available calcium channel blockers may be categorized into four groups based upon different chemical structures:
- Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 298:267.
- Bayer R, Rodenkirchen R, Kaufmann R, et al. The effects of nifedipine on contraction and monophasic action potential of isolated cat myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 301:29.
- Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 1979; 44:832.
- Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 1979; 44:817.
- Kitakaze M, Asanuma H, Takashima S, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000; 101:311.
- Casolo GC, Balli E, Poggesi L, Gensini GF. Increase in number of myocardial ischemic episodes following nifedipine administration in two patients. Detection of silent episodes by Holter monitoring and role of heart rate. Chest 1989; 95:541.
- Joyal M, Cremer KF, Pieper JA, et al. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol 1985; 56:413.
- Bache RJ, Dymek DJ. Effect of diltiazem on myocardial blood flow. Circulation 1982; 65:I19.
- Krikler DM. Calcium antagonists for chronic stable angina pectoris. Am J Cardiol 1987; 59:95B.
- Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27:311.
- Sherman LG, Liang CS. Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial. Am J Cardiol 1983; 51:706.
- Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994; 73:28A.
- Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849.
- Agre K. An overview of the safety and efficacy of nicardipine in clinical trials. Am J Cardiol 1987; 59:31J.
- Dargie HJ, Lynch PG, Krikler DM, et al. Nifedipine and propranolol: a beneficial drug interaction. Am J Med 1981; 71:676.
- Subramanian VB, Bowles MJ, Khurmi NS, et al. Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina. Am J Cardiol 1982; 50:696.
- Wallace WA, Wellington KL, Murphy GW, Liang CS. Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris. Am J Cardiol 1989; 63:414.
- Klinke WP, Kvill L, Dempsey EE, Grace M. A randomized double-blind comparison of diltiazem and nifedipine in stable angina. J Am Coll Cardiol 1988; 12:1562.
- Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83:507.
- Weiner DA, Klein MD. Verapamil therapy for stable exertional angina pectoris. Am J Cardiol 1982; 50:1153.
- Subramanian VB, Lahiri A, Paramasivan R, Raftery EB. Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. Lancet 1980; 1:841.
- Brodsky SJ, Cutler SS, Weiner DA, et al. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. Circulation 1982; 66:569.
- Pine MB, Citron PD, Bailly DJ, et al. Verapamil versus placebo in relieving stable angina pectoris. Circulation 1982; 65:17.
- Frishman WH, Klein NA, Klein P, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. Am J Cardiol 1982; 50:1164.
- Subramanian VB, Bowles MJ, Davies AB, Raftery EB. Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. Am J Cardiol 1982; 50:1158.
- Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981; 71:443.
- Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. Am J Cardiol 1987; 59:215.
- Cutler NR, Anders RJ, Jhee SS, et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 1995; 75:1102.
- Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol 1982; 49:567.
- Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol 1982; 49:560.
- Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2:1129.
- Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol 1986; 57:6.
- Nadeau C, Hilton D, Savard D, et al. Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris. Am J Cardiol 1995; 75:555.
- Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol 1994; 74:9.
- van Dijk RB, Lie KI, Crijns HJ. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988; 9:1194.
- Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985; 71:951.
- Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol 1985; 55:69B.
- Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81:128.
- Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol 1998; 81:133.
- Dunselman P, Liem AH, Verdel G, et al. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). Eur Heart J 1997; 18:1755.
- Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620.
- Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.
- Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92:1074.
- Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009; 122:356.
- Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275:423.
- Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.
- Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.
- Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929.
- MECHANISM OF ACTION
- CARDIOVASCULAR AND ADVERSE SIDE EFFECTS
- Dihydropyridines versus verapamil or diltiazem
- Combination therapy with beta blockers
- - Verapamil
- - Nifedipine
- - Amlodipine
- - Felodipine
- ARE CALCIUM CHANNEL BLOCKERS SAFE?
- RECOMMENDATIONS OF OTHERS